Thus, the occupancy of SERT with duloxetine appears adequate for treatment of MDD and might complement the low NET occupancy, because MDD is a multi-pathology disease involving both NET and SERT (Gryglewski et al., 2014; Moriguchi et al., 2017). This evidence concerns the gene SLC6A4 and major depressive disorder.